相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis
Lukas Ronner et al.
BLOOD (2020)
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
Heinz Gisslinger et al.
LANCET HAEMATOLOGY (2020)
The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design
Munyaradzi Dimairo et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis
Alessandra Carobbio et al.
BLOOD ADVANCES (2019)
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
Tiziano Barbuil et al.
LEUKEMIA (2018)
The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts
Robyn Marie Scherber et al.
LEUKEMIA & LYMPHOMA (2017)
NCCN Guidelines® Insights Myeloproliferative Neoplasms, Version 2.2018 Featured Updates to the NCCN Guidelines
Ruben A. Mesa et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study
Tiziano Barbui et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone
J-J Kiladjian et al.
LEUKEMIA (2016)
Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis
Tiziano Barbui et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera
Heinz Gisslinger et al.
BLOOD (2015)
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology
Tiziano Barbui et al.
BLOOD (2014)
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
Giovanni Barosi et al.
BLOOD (2013)
Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Roberto Marchioli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
n-3 Fatty Acids in Patients with Multiple Cardiovascular Risk Factors
Maria Carla Roncaglioni et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
Robyn M. Emanuel et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Exact Confidence Bounds Following Adaptive Group Sequential Tests
Werner Brannath et al.
BIOMETRICS (2009)
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
LANCET (2009)
Efficacy and safety of low-dose aspirin in polycythemia vera
R Landolfi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
分享论文
